Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

Journal Article (Journal Article)

Full Text

Duke Authors

Cited Authors

  • Jackson, DO; Peace, KM; Hale, DF; Vreeland, TJ; Choy, G; Nejadnik, B; Greene, JM; Schneble, EJ; Berry, JS; Trappey, AF; Hardin, MO; Clifton, GT; Herbert, GS; Mittendorf, E; Holmes, JP; Peoples, GE

Published Date

  • October 1, 2016

Published In

Volume / Issue

  • 27 /

Start / End Page

  • vi366 -

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdw378.23

Citation Source

  • Scopus